Evidence map›Paper›PMID 33708854›Full record

ArticleAnnals of translational medicine2021

Systemic inflammation is associated with inferior disease control and survival in stage III non-small cell lung cancer.

Emily Keit, Brendan Coutu, Weining Zhen, Chi Zhang, Chi Lin, Nathan Bennion, Apar Kishor Ganti, Vinicius Ernani, Michael Baine

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Emily KeitDepartment of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
Brendan CoutuDepartment of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
Weining ZhenDepartment of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
Chi ZhangDepartment of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
Chi LinDepartment of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
Nathan BennionDepartment of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
Apar Kishor GantiDivision of Hematology/Oncology, Department of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Vinicius ErnaniDivision of Hematology/Oncology, Department of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Michael BaineDepartment of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
University of Nebraska Medical Center · USVA Nebraska Western Iowa Health Care System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe systemic immune-inflammation index (SII) correlates with patient survival in various types of solid malignancies, including non-small cell lung cancer (NSCLC). However, limited information is available on the prognostic implication and disease-specific survival of SII in patients undergoing definitive chemoradiation therapy (CRT) for stage III NSCLC.

methodsWe retrospectively reviewed 125 patients who underwent curative intent CRT for stage III NSCLC with sufficient laboratory assessment from 2010-2019. SII was calculated at the time of diagnosis as platelet count × neutrophil count/lymphocyte count. Chi-squared analysis was used to compare categorical variables. A Kaplan-Meier analysis was performed to estimate progression-free survival (PFS), disease specific survival (DSS), and overall survival (OS) rates, with Cox regression used to determine absolute hazards.

resultsAt a median follow-up of 19.7 months, 5-year OS, DSS, and PFS rates were 22.6%, 30.9%, and 13.4%, respectively. A low SII (<1,266) at diagnosis was independently associated with an improved OS (HR: 0.399, 95%, CI: 0.247-0.644, P<0.001), DSS (HR: 0.383, 95%, CI: 0.228-0.645, P<0.001), and PFS (HR: 0.616, 95%, CI: 0.407-0.932, P=0.022). We did not detect an association between SII and freedom from recurrence (FFR), freedom from locoregional recurrence (FFLRR), or freedom from distant recurrence (FFDR). NSAID (1,483.4

conclusionsLow SII scores were independently associated with improved OS, DSS, and PFS rates in patients with stage III NSCLC undergoing definitive CRT. NSAIDs and statin usage may be associated with lower SII at diagnosis of NSCLC. This study suggests that SII may be an effective prognostic indicator of patient mortality. Further investigation of the therapeutic potential of these agents in patients with an elevated SII in this setting may be warranted.

Indexed as

inflammationNon-small cell lung cancer (NSCLC)systemic immune-inflammation index (SII)

Identifiers

PMID33708854
PMCPMC7940875
OpenAlexW3124626310

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.